Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited, has appointed Dr. Sridevi Khambhampaty as its new Chief Executive Officer (CEO), effective from September 19, 2024.
Dr. Khambhampaty is a recognized leader in the biologics industry with over 22 years of experience, having developed products for the Indian, US, and EU markets. She is known for her technical expertise and leadership skills, having built high-performing teams throughout her career. With a PhD in Biophysics from NCBS-TIFR Bangalore and a postdoctoral fellowship from Stanford University, California, her strong understanding of regulatory and compliance requirements, combined with her business acumen, positions her to drive significant growth for Shilpa Biologics.
Dr. Khambhampaty’s previous roles include work at Lymphoma & Leukemia Research Foundation, Dr. Reddy’s, Intas Pharmaceuticals, and most recently, Syngene International Ltd.
